ABSTRACT
The objective of our study was to investigate whether curcumin protects against reserpine-induced gastrointestinal mucosal lesions (GMLs) in rats and to explore the mechanism of curcumin's action. Sprague-Dawley rats were randomly divided into four groups: control group, reserpine-treated group, reserpine treatment group with curcumin at high dose (200 mg/kg), and reserpine treatment group with curcumin at low dose (100 mg/kg). Rats in reserpine-treated group were induced by intraperitoneally administered reserpine (0.5 mg/kg) for 28 days. TUNEL staining and hematoxylin and eosin staining were used to evaluate the apoptotic cells and morphologic changes. In addition, to explore the mechanism of curcumin in protecting GMLs, we used serum of experimental rats to assess the level of vasoactive intestinal peptide (VIP), gastrin, interleukin-6, interleukin-10, tumor necrosis factor-α and interferon-γ by ELISA and radioimmunoassay. The protein levels of NF-κB, p-IκB-α, IκB-α, Bcl-2, Bax, and cleaved-caspase-3 were examined by western blot analysis. Data were analyzed with SPSS 19.0 software package. Curcumin treatment prevented tissue damage and cell death in the reserpine-treated rats and effectively decreased inflammatory response and balanced the expression of VIP and gastrin in the reserpine-treated rats. NF-κB, p-IκB-α, Bax, and cleaved-caspase-3 were increased in the reserpine group, but the curcumin high-dose group inhibited them. Curcumin can target the IκB-α/NF-κB pathway to inhibit inflammatory response and regulate the level of VIP and gastrin in reserpine-induced GML rats.
Subject(s)
Antihypertensive Agents/adverse effects , Curcumin/administration & dosage , Gastric Mucosa/drug effects , Gastrins/genetics , Gastrointestinal Diseases/drug therapy , I-kappa B Proteins/metabolism , NF-kappa B/metabolism , Reserpine/adverse effects , Vasoactive Intestinal Peptide/genetics , Animals , Gastric Mucosa/injuries , Gastric Mucosa/metabolism , Gastrins/metabolism , Gastrointestinal Diseases/etiology , Gastrointestinal Diseases/genetics , Gastrointestinal Diseases/metabolism , Humans , I-kappa B Proteins/genetics , Male , NF-kappa B/genetics , Rats , Rats, Sprague-Dawley , Signal Transduction/drug effects , Vasoactive Intestinal Peptide/metabolismABSTRACT
OBJECTIVE: To explore the effect of Linguizhugan decoction on hyperlipidemia rats with caloric restriction. METHODS: The hyperlipidemia model of rat was induced by high fat diet for 8 weeks. After the model was established, 26 rats were randomly divided into 4 groups: the control group (n = 6), the model group (n = 6), the intermittent fasting (IF) group (n = 8), and the IF and herbal medicine (IFH) group (n = 6). IF group was applied intermittent fasting every other day. The IFH group was given Linguizhugan decoction every day and intermittent fasting every other day. Blood samples were taken at the end of 16 weeks, and serum ghrelin and lipid was tested. RESULTS: Serum ghrelin in the IF group significantly increased (P < 0.01). Serum ghrelin in IFH group was lower than the IF group (P < 0.05), but higher than the model group (P < 0.01). CONCLUSION: Linguizhugan decoction may play a part in regulation of energy and appetite in hyperlipidemia rats with IF.